Exacerbation of prothrombin time-international normalized ratio before second polymyxin B cartridge hemoperfusion predicts poor outcome of patients with severe sepsis and/or septic shock

Opal, 2003, Endotoxin as a drug target, Crit Care Med, 31, 57, 10.1097/00003246-200301001-00009 Kellum, 2007, A targeted extracorporeal therapy for endotoxemia: the time has come, Crit Care, 11, 137, 10.1186/cc5918 Shimizu, 2009, The clinical significance of serum procalcitonin levels following direct hemoperfusion with polymyxin B-immobilized fiber column in septic patients with colorectal perforation, Eur Surg Res, 42, 109, 10.1159/000187169 Mitaka, 2009, A longer duration of polymyxin B-immobilized fiber column hemoperfusion improves pulmonary oxygenation in patients with septic shock, Shock, 32, 478, 10.1097/SHK.0b013e3181a2a978 Shoji, 2003, Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin), Ther Apher Dial, 7, 108, 10.1046/j.1526-0968.2003.00005.x Mitaka, 2011, Polymyxin B-immobilized fiber column hemoperfusion therapy for septic shock, Shock, 36, 332, 10.1097/SHK.0b013e318225f839 Sato, 2003, Endotoxin adsorption by polymyxin B immobilized fiber column in patients with systemic inflammatory response syndrome: the Japanese experience, Ther Apher Dial, 7, 252, 10.1046/j.1526-0968.2003.00006.x Dellinger, 2008, Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008, Crit Care Med, 36, 296, 10.1097/01.CCM.0000298158.12101.41 Dellinger, 2013, Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012, Crit Care Med, 41, 580, 10.1097/CCM.0b013e31827e83af Cruz, 2009, Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial, JAMA, 301, 2445, 10.1001/jama.2009.856 Kim, 2013, An increase in red blood cell distribution width from baseline predicts mortality in patients with severe sepsis or septic shock, Crit Care, 17, R282, 10.1186/cc13145 Takeyama, 2012, Time to initiation of treatment with polymyxin B cartridge hemoperfusion in septic shock patients, Blood Purif, 33, 252, 10.1159/000336341 Rivers, 2001, Early goal directed therapy in the treatment of severe sepsis and septic shock, N Engl J Med, 345, 1368, 10.1056/NEJMoa010307 Dellinger, 2004, Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock, Crit Care Med, 32, 858, 10.1097/01.CCM.0000117317.18092.E4 Ishizuka, 2014, Impact of prothrombin time-international normalized ratio on outcome of patients with septic shock receiving polymyxin B cartridge hemoperfusion, Surgery, 156, 168, 10.1016/j.surg.2014.03.009 Gando, 2013, A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis, Crit Care, 17, R297, 10.1186/cc13163 Kaneko, 2011, Diagnostic criteria and laboratory tests for disseminated intravascular coagulation, J Clin Exp Hematop, 51, 67, 10.3960/jslrt.51.67 Yanagida, 2013, Normal prothrombinase activity, increased systemic thrombin activity, and lower antithrombin levels in patients with disseminated intravascular coagulation at an early phase of trauma: comparison with acute coagulopathy of trauma-shock, Surgery, 154, 48, 10.1016/j.surg.2013.02.004 Gando, 2013, A multicenter, prospective validation study of the Japanese Association for Acute Medicine disseminated intravascular coagulation scoring system in patients with severe sepsis, Crit Care, 17, R111, 10.1186/cc12783 Yamato, 2013, Effective combination therapy of polymyxin-B direct hemoperfusion and recombinant thrombomodulin for septic shock accompanied by disseminated intravascular coagulation: a historical controlled trial, Ther Apher Dial, 17, 472, 10.1111/1744-9987.12112 Levi, 1999, Disseminated intravascular coagulation, N Engl J Med, 341, 586, 10.1056/NEJM199908193410807 Corrigan, 1977, Heparin therapy in bacterial septicemia, J Pediatr, 91, 695, 10.1016/S0022-3476(77)81017-2 Taylor, 1987, Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon, J Clin Invest, 79, 918, 10.1172/JCI112902 Emerson, 1989, Efficacy of antithrombin III supplementation in animal models of fulminant Escherichia coli endotoxemia or bacteremia, Am J Med, 87, 27 Vincent, 2013, A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation, Crit Care Med, 41, 2069, 10.1097/CCM.0b013e31828e9b03